Enzymatic Prenylation and Oxime Ligation for the Synthesis of Stableand Homogeneous Protein–Drug Conjugates for Targeted Therapy

 

 

새로운 단백질 표적 치료제인 인공항체-약물 복합체의 개발

  

Joong-jae Lee, Hyo-Jung Choi, Misun Yun, YingJin Kang, Ji-Eun Jung, Yiseul Ryu,Tae Yoon Kim, Young-je Cha, Hyun-Soo Cho, Jung-Joon Min, Chul-Woong Chung, andHak-Sung Kim

  

 

김학성 교수와 이중재 박사는 (주)레고켐과 공동으로 인공 항체 골격인 리피바디에 효소-화학적인 방법으로 항암제를 결합시킨 새로운 단백질 표적 치료제를 개발하였다. 리피바디-약물 복합체는 동물 실험에서 우수한 암 치료 효능을 보였으며, 향후 혁신적 표적 치료제로 개발될 것으로 기대된다.

관련 연구는 Angewandte Chemie에 Hot Paper 로 발표되었다.

Enzymatic Prenylation and Oxime Ligation for the Synthesis of Stable and Homogeneous Protein–Drug Conjugates for Targeted Therapy

 

Development of novel protein-drug conjugates for targeted therapy

  

Joong-jae Lee, Hyo-Jung Choi, Misun Yun, YingJin Kang, Ji-Eun Jung, Yiseul Ryu,Tae Yoon Kim, Young-je Cha, Hyun-Soo Cho, Jung-Joon Min, Chul-Woong Chung, andHak-Sung Kim

  

Prof. Hak-Sung Kin, PhD. Joong-Jae Lee and LegoChem Co., Ltd. developed novel target drugs for cancer. The drug which was chemoenzymatically conjugated with repebody shows remarkable antitumor activity in vivo. This method would be developed as an innovative targeted therapy.

This research was selected for Hot Paper at Angewandte Chemie.